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The present study evaluates for the first time in dogs, the kinetics of green tea catechins and their metabolic forms in plasma and urine. Ten beagles
were administered 173 mg (12·35 mg/kg body weight) of catechins as a green tea extract, in capsules. Blood samples were collected during 24 h after
intake and urine samples were collected during the following periods of time: 0–2, 2–6, 6–8 and 8–24 h. Two catechins with a galloyl moiety and
three conjugated metabolites were detected in plasma. Most of the detected forms in plasma reached their maximum plasma concentration (Cmax) at
around 1 h. Median Cmax for (2 )-epigallocatechin-3-gallate (EGCG), (2)-epicatechin-3-gallate (ECG), (2)-epigallocatechin glucuronide (EGC-
glucuronide), (2)-epicatechin glucuronide (EC-glucuronide), (2)-epicatechin sulphate (EC-sulphate) were 0·3 (range 0·1–1·9), 0·1 (range
0–0·4), 0·8 (range 0·2–3·9), 0·2 (range 0·1–1·7) and 1 (range 0·3–3·4) mmol/l, respectively. The areas under the plasma concentration v. time
curves (AUC0!24) were 427 (range 102–1185) mmol/l £ min for EGC-glucuronide, 112 (range 53–919) mmol/l £ min for EC-sulphate, 71
(range 26–306) mmol/l £ min for EGCG, 40 (range 12–258) mmol/l £ min for EC-glucuronide and 14 (range 0·1–124) mmol/l £ min for ECG.
The values of mean residence time (MRT0!24) were 5 (range 2–16), 2 (range 1–11), 10 (range 2–13), 3 (range 2–16) and 2·4 (range 1–18) h
for EGCG, ECG, EGC-glucuronide, EC-glucuronide and EC-sulphate, respectively. In urine, catechins were present as conjugated forms, suggesting
bile excretion of EGCG and ECG. Green tea catechins are absorbed following an oral administration and EGC-glucuronide is the metabolic form
that remains in the organism for a longer period of time, suggesting that this compound could suffer an enterohepatic cycle.
Flavanols: Metabolites: Pharmacokinetic: Extract: Plasma: Dogs: Urine
Green tea is the most consumed beverage in the world aside
from water, and has recently attracted significant attention,
both in the scientific and in consumer communities for its
health benefits for a variety of disorders, protection against
cancer and promotion of weight loss. The beneficial effects of
green tea are attributed to the polyphenolic compounds present
in this beverage. Green tea polyphenols have been extensively
studied as CVD and cancer chemopreventive agents(1 – 4). The
natural product (2 )-epigallocatechin-3-gallate (EGCG) is
the major polyphenolic constituent found in green tea (dried
fresh leaves of the plant Camellia sinensis)(5). Several other fla-
vanols are also found in lower abundance in this beverage,
including (2 )-epicatechin-3-gallate (ECG), (2)-epigallocate-
chin (EGC), (2)-epicatechin (EC) and (þ)-catechin (Fig. 1).
More than 50 % of the mass of this catechin combination is
composed of EGCG which has proven beneficial effects in
studies of Parkinson’s disease(6), Alzheimer’s disease(7,8),
stroke(9,10), obesity(11), diabetes(12,13), chemoprevention(14 – 16)
and high antioxidant activity(17). It has also been demonstrated
to be a potential anti-inflammatory molecule(18,19).
The metabolic fate of polyphenols in the organism after
their ingestion as food or beverages should be thoroughly
studied, since these are the active forms that may generate
the biological effect of these compounds. Green tea catechin
in vivo activity is limited by effective concentrations at
target sites, since it is assumed that plasma concentration of
catechins and their metabolites are dynamically equilibrated
with their concentration at successfully reached tissues. The
changes observed in plasma concentrations reflect transform-
ations the metabolites undergo in the tissues. It is, therefore,
of special interest to study in depth the behaviour of catechins
in the organism, that is, to evaluate the process of absorption,
distribution, metabolism and excretion through plasma and
urine levels of their metabolites. The use of enzymatic
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hydrolysis for the determination of tea catechins in plasma has
been extensively applied in previous studies(20 – 26). However,
information about individual metabolites is not available in
these studies, nor have they carried out a pharmacokinetic
evaluation of the specific active molecules that could reach
target cells.
The use of dogs as a model has been shown to be useful in
evaluating the absorption of polyphenols from different food
sources, allowing identification of specific forms present in
the systemic circulation. In a previous study we evaluated
in plasma, the kinetics of flavanones and their metabolites in
beagle dogs after oral ingestion of a grapefruit fruit extract(27).
Our earlier results demonstrated the absorption of grapefruit
flavanone via the presence of its metabolites in plasma.
Swezey et al. (28) studied in beagles the absorption, tissue dis-
tribution and elimination of 4-[3H]epigallocatechin-3-gallate
after intravenous and oral administration of radiolabelled
EGCG. Their results indicate that, after oral administration,
EGCG is rapidly and widely distributed to tissues where it
can exert its biological effects.
Therefore, the purpose of the current study is to assess, for the
first time in beagles, the major flavanol forms in plasma and
urine after oral administration of a green tea extract. We also
evaluate the pharmacokinetics of these metabolic forms in
both biological matrices by considering their biotransformation,




EGCG (95 %), EGC and ECG (98 %) from green tea, (2 )-epi-
catechin and blank dog plasma were purchased from
Sigma-Aldrich (St Louis, MO, USA). Ethylgallate (internal
standard) was purchased from Extrasynthese (Genay, France).
Methanol, acetonitrile and n-n-dimethylformamide (HPLC
grade) and formic acid were purchased from Scharlau Chemie
SA (Barcelona, Spain); o-phosphoric acid (85 %) was purchased
from Panreac Quimica SA (Barcelona, Spain). Ultrapure water
(Milli-Q) was obtained from a Millipore System (Bedford,
MA, USA). Green tea capsules contained 124 mg EGCG, 9 mg
EGC, 21 mg EC, 19 mg ECG, 4·38 mg (þ)-catequin and talc
as an excipient. The capsules were stored at room temperature
and protected from extreme environmental conditions.
Subjects and study design
Twelve healthy adult (14 (SD 3) kg) female beagle dogs were
randomly chosen and were deprived of food overnight before
the experiment. The dogs were orally administered with two
capsules containing 200 mg green tea extract; two dogs were
chosen as a control and were given an excipient containing
talc. Blood samples (5 ml) were drawn before capsule admin-
istration and at the following times: 30, 45, 60, 75, 90 min, 2,
4, 8 and 24 h and were collected in vacutainer tubes containing
EDTA as anticoagulant (Becton Dickinson, Franklin Lakes,
NJ, USA). Plasma was obtained after blood centrifugation at
1000 g for 10 min and stored in Eppendorf tubes at 2808C
until analysis. Urine samples were taken before and at the foll-
owing intervals: 0–2, 2–6, 6–8 and 8–24 h, after oral
administration of green tea extract. Urine was acidified with
200 mM-HCl and stored at 2808C until analysis.
The study was carried out at the University of Zaragoza
(Spain) in accordance with the Guide for the Care and Use
of Laboratory Animals (29). The study protocol was approved
by the Ethics Committee of the University of Zaragoza.
Fig. 1. Chemical structures of green tea catechins.

















Sample extraction procedure for green tea catechins and their
metabolites
Green tea catechins in plasma and urine were obtained by solid-
phase extraction. Dog plasma samples were treated as follows:
280ml internal standard (2525 nmol/l) were added to 1 ml
plasma and then mixed with 370ml antioxidant solution
(containing 0·2 g/ml ascorbic acid and 1 mg/ml EDTA) and
with 20ml o-phosphoric acid. After 2 min of vortex mixing,
samples were diluted with 3 ml water. A solid-phase extraction
(30 mg) with a Waters Oasisw HLB 30mm ninety-six-well
plate (Milford, MA, USA) was applied to the mixture.
Cartridge activation was achieved by adding 1 ml: methanol,
water, 70 % (v/v) n-n-dimethylformamide containing 0·1 %
(v/v) formic acid and water, respectively. The cartridges were
washed with 2 ml water and 1 ml 30 % (v/v) methanol. Tea
catechin metabolites were then eluted with 0·7 ml 70 % (v/v)
n-n-dimethylformamide containing 0·1 % (v/v) formic acid.
After filtration with a 4 mm, 0·45mm polytetrafluoroethane
filter (Waters Corporation, USA), 20ml of the resulting filtrate
was injected into the LC–MS/MS system.
Preparation of standards and sample treatments were per-
formed in a darkened room with a red safety light to avoid
oxidation of the analytes.
Instrumentation
LC–MS/MS. Plasma and urine green tea catechin metabo-
lites were identified and quantified by LC–MS/MS analysis.
LC analysis was performed using a Perkin-Elmer series 200
(Norwalk, CT, USA) equipped with a quaternary pump and a
refrigerated auto-sampler. A Luna C18 column (50 £ 2·0 mm
internal diameter, 5mm) from Phenomenex (Torrance, CA,
USA) was used at room temperature, and the injected
volume was 20ml. Gradient elution was carried out with
water (0·1 % formic acid) and acetonitrile (0·1 % formic
acid) at a constant flow-rate of 600ml/min. A gradient profile
with the following proportions (v/v) of acetonitrile (0·1 %
formic acid) was applied: 0 min, 0·5 %; 3 min, 15 %; 6 min,
100 %; 9 min, 100 %. A triple quadrupole mass spectrometer
(API 3000; Applied Biosystems, PE Sciex, Concord, Ontario,
Canada), equipped with a Turbo IonSpray source was used to
obtain the MS and MS/MS data. Prior to its use, the instru-
ment was checked to meet the acceptance specifications
defined by the manufacturer. The triple quadrupole mass spec-
trometer was calibrated with the Turbo IonSpray using a test
mixture solution of poly (propyleneglycol) obtained from
Applied Biosystems. The mass spectrometer was calibrated
so that mass accuracy specifications and sensitivity were
achieved over the entire mass range. Turbo Ionspray source
settings were as follows: capillary voltage, 3500 V; nebulizer
gas (N2), 10 (arbitrary units); curtain gas (N2), 12 (arbitrary
units); collision gas (N2), 4 (arbitrary units); focusing poten-
tial, 200 V; entrance potential, 10 V; drying gas (N2) heated
to 4008C and introduced at a flow rate of 8000 cm3/min. The
declustering potential and the collision energy were optimized
for each compound in infusion experiments: individual stan-
dard solutions (21·8–34·5mmol/l) dissolved in 80:20 mobile
phase were infused at a constant flow rate of 5ml/min into
the mass spectrometer using a model syringe pump (Harvard
Apparatus, Holliston, MA, USA). Full scan data were acquired
by scanning from m/z 100 to 800 in profile mode, using a cycle
time of 2 s with a step size of 0·1 unit. For MS/MS, a product
ion scan utilizing a cycle time of 2 s was used. MS/MS product
ions were produced by collision-activated dissociation of
selected precursor ions in the collision cell of the triple–quad-
rupole mass spectrometer and mass analysed using the second
analyser of the instrument. The multiple reaction monitoring,
the method of choice owing to its highest selectivity and sen-
sitivity in quantitative LC–MS/MS, has monitored several
transitions for each analysis. Both quadrupoles (Q1 and Q3)
were operated at unit resolution. The criteria for identification
of green tea catechin metabolites such as retention time, mul-
tiple reaction monitoring transition as mentioned earlier and
transitions 481 ! 305 ((2)-epigallocatechin-glucuronide),
385 ! 305 ((2 )-epigallocatechin-sulphate), 305 ! 125
((2 )-epigallocatechin), 465 ! 289 ((2 )-epicatechin-glucuro-
nide), 369 ! 289 ((2 )-epicatechin-sulphate (m/z 369/289),
289 ! 245 ((2 )-epicatechin) (at a higher declustering poten-
tial value) were chosen as confirmation of the multiple reac-
tion monitoring trace for each metabolite in collisionally
induced dissociation MS/MS experiments(30,31).
Safety considerations
Dog plasma samples were considered as potentially infectious.
We have respected general guidelines regarding working with
biological fluids, organic solvents and acids. Universal precau-
tions regarding handling of chemicals and fluids were applied.
Pharmacokinetic analysis
Pharmacokinetic parameters were determined by means of a
non-compartmental analysis using the WinNonlinw Professional
software version 3.3 (Pharsight Corporation, USA). The linear
trapezoidal method was used to calculate the area under the
plasma concentration curve (AUC0– t) from time 0 until the last
detectable concentration. The maximum plasma concentration
(Cmax) and the time needed to reachCmax (Tmax) were determined
by visual inspection of the experimental data. MRT was esti-
mated by means of the AUMC/AUC ratio, where AUMC is
from the first measurement of the plasma concentration v. time
curve. The maximum accumulated amount of catechins excreted
in urine was also determined.
Statistical analysis
The pharmacokinetic parameters of green tea catechins and its
metabolites were compared by one-way ANOVA on ranks
followed by a Scheffe´’s multiple comparison test. P,0·05
was considered significant. The statistical analysis was per-
formed using SPSS software version 11.5 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Green tea catechins present in plasma and urine samples
Two catechins with a galloyl moiety were present in plasma
(EGCG and ECG) and three conjugated forms were also
detected, however, only the conjugated forms of EC and EGC
were present in urine. Regarding conjugated catechins found

















in plasma, EGC was mainly present in the glucuronide form
while EC was both in the glucuronide and sulphate form.
Figs. 2 and 3 show plasma concentration v. time curves corre-
sponding to the catechins and catechin metabolites detected
in plasma. In urine tea catechins EGC and EC were mostly
present in the conjugated forms, as glucuronides and sulphates.
Pharmacokinetics of green tea catechins after oral intake of
green tea extract
The following pharmacokinetic parameters corresponding
to each of the catechins and catechin metabolites (Cmax,
AUC0!24, MRT0!24, Tmax) are summarized in Table 1.
Values are expressed as median and range, together with the
results of the statistical analysis carried out. No significant
statistical differences were found between most of the pharma-
cokinetic parameters corresponding to both catechins and
catechin conjugates. This was not the case, however, with
AUC0!24, whose values showed significant differences
between (2)-epigallocatechin glucuronide (EGC-glucuronide)
and (2 )-epicatechin glucuronide (EC-glucuronide), and EGC-
glucuronide and ECG.
Fig. 4 represents the curves of accumulated excretion in
urine for each of the conjugated catechins. Values are
expressed as means and standard deviations for ten dogs.
Discussion
During the past 10 years, there have been several pharmacoki-
netics studies(22 – 26,32 – 36) with green tea catechins where only
unchanged catechins were evaluated, suggesting that the cal-
culated bioavailability in these studies were probably overes-
timated. Thus, additional studies, where catechin metabolites
are determined, are necessary. Once the polyphenol has been
ingested it may suffer a number of changes during absorption
and when it reaches the systemic circulation it may be present
in its native or in its metabolic form. Thus, in order to under-
stand the mechanism by which polyphenols exert their
beneficial effects, extensive data from metabolic and distri-
bution studies are required. Previous studies with green tea
catechins have applied different forms of administration,
including green tea as a beverage, green tea extracts, pure cate-
chins (EGCG) or polyphenolic preparations (Polyphenon E),
demonstrating that the form of administration has a pronounced
effect on the bioavailability of these compounds.
In the present study, we have administered green tea cate-
chins as a green tea extract contained in capsules. The pre-
sence of conjugated EGCG forms in dog plasma was not
detected, only the free forms of EGCG and ECG were present.
The present results were in accordance with Chow et al. (23),
who indicated that after ingestion of EGCG and Polyphenon
E (a tea polyphenol preparation) by human volunteers,
plasma EGCG was mainly present in the free (unconjugated)
form and may be eliminated in faeces by biliar excretion.
The presence of unconjugated forms of EGCG and ECG in
dog plasma could be explained by the fact that EGCG and
ECG have a galloyl group on the C ring and EGCG has a
hydroxyl group in the 50 position (Fig. 1). Possibly this
group could have decreased access to the active site of uridine
diphosphate glucuronosyl transferase, since EGCG (galloyl
group and hydroxyl in 50 position) has shown an even lower
glucuronidation rate than that of ECG(37). Another expla-
nation, as has been reported before, may be the fact that
green tea catechins can be strong inhibitors of phase II
enzymes (caffeic o-methyltransferases, uridine diphosphate
glucuronosyl transferases and sulfotransferases). It has also
been found that methylation of EGC can be strongly inhibited
by ECG and EGCG(38), justifying the absence of methylated
conjugate.
As can be observed in Table 1, EGC-glucuronide showed
the highest AUC0!24 values and also the highest MRT0!24,
indicating that this specific metabolite remains within the
organism for approximately 10 h. Considering that in the
orally administered green tea extract, EGC is in the lowest
proportion (4·7 %) compared to the other catechins, these
high AUC and MRT values may be due to an enterohepatic
cycle. The glucuronide formation could take place during
EGC absorption and/or in the liver by the action of uridine
diphosphate glucuronosyl transferase. The resulting conju-
gated product (EGC-glucuronide) could be again excreted to
the intestinal lumen through the bile. This conjugate could
be hydrolysed by action of the intestinal enzyme b-glucuroni-
dase generating EGC that could once again be absorbed, gen-
erating the enterohepatic cycle, and remaining in the organism
Fig. 2. Time v. plasma concentration curves for the following catechin metab-
olites: (2 )-epigallocatechin glucuronide (V), (2 )-epicatechin glucuronide (B)
and (2 )-epicatechin sulphate (O) for ten beagles receiving 173 mg green tea
catechins. Values are means with their standard deviations depicted by verti-
cal bars.
Fig. 3. Time v. plasma concentration curves for the following catechins: (2)-epi-
gallocatechin-3-gallate (V) and (2)-epicatechin-3-gallate (B) for ten beagles
receiving 173 mg green tea catechins. Values are means with their standard
deviations depicted by vertical bars.

















for a longer period of time. As has been reported before, the
health benefits of flavonoids can be due to different properties
of their major phase II metabolites, such as antioxidants, pro-
tein inhibitors of human Multidrug Resistance Proteins 1 and
2, and monocyte–endothelial cell interaction(39 – 41). The high
MRT value is very interesting because EGC-glucuronide
could be a potentially active molecule that remains in the
organism long enough to exert its beneficial actions.
Tmax and AUC values for EGCG compared well with data
generated in previous studies with human subjects(21,24,34,42).
However, Cmax values differ, suggesting that the bioavailabil-
ity of green tea catechins is variable and could be due to
differences in species, quantity and form of catechin adminis-
tration. It should be considered that the presence or absence
and the time-dependent appearance and disappearance of
specific catechin metabolites in plasma can vary significantly
among subjects and species, suggesting that interindividual
variation is an important factor that must always be taken
into consideration when performing dietary assessment
studies.
It is assumed that plasma concentrations of catechins and
their metabolites are equilibrated with their concentrations
at successfully reached tissues, Swezey et al. (28) dem-
onstrated that radioactive EGCG was distributed to a variety
of epithelial tissues in beagles; the highest concentrations
being observed in the liver and gastrointestinal tract
tissues. However, additional investigation is needed on tissue
distribution, specifically with the metabolites present in
plasma after oral intake, since these compounds, such as
EGC-glucuronide, are the ones that remain in the organism
for a longer period of time.
The maximum amount of metabolites excreted in urine is
directly related to the quantity of the absorbed compound(43).
In Fig. 4, the accumulative amount excreted per sampling
interval is referred to the mid-point of the collection period,
for example, for the 0–2 h period, the mid-point would be
1 h; for the interval 2–6 h, the mid-point would be 4 h. The
values of the 7 h mid-point correspond to the interval 6–8 h.
Unfortunately not all the subjects could urinate during these
hours, obtaining less sample and consequently, lower values.
This tendency is only observed in the graphics with mean
values; individual graphics do not show this tendency. As pre-
sented in Fig. 4, EC conjugates are the metabolites with the
highest excreted amounts, sulphates being the major ones;
(2 )-epicatechin sulphate is the metabolite with the highest
maximum amount excreted. The cumulated urine excretion
during 24 h after ingestion of the green tea extract accounted
for 1·12 and 0·58 % for EC and EGC, respectively, suggesting
that a considerable amount of these metabolites could have
bile excretion as an elimination pathway as well. On the
other hand, the absence of unconjugated EGCG and ECG in
urine may possibly be due to most of the absorbed unconju-
gated EGCG being excreted through the bile(28,44).
To our knowledge, we have evaluated, for the first time in
beagles, the pharmacokinetics of green tea catechins and their
metabolites in plasma and urine after oral administration of a
green tea extract. We have demonstrated that catechins are
absorbed from the intestine as their intact form or as conju-
gates following oral administration, and that the conjugated
catechins remain in the organism for a longer period of time
probably due to an enterohepatic cycle. The present finding
is very interesting because if the conjugated metabolites of
green tea catechins are indeed active molecules, their MRT
values are high enough to exert potentially beneficial effects.
These data also provide a general model for future pharmaco-
kinetics studies.
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